皮肤病药物临床试验的质量控制要点及特征分析
2023-08-03时歆未崔贞黄艳平朱全刚
时歆未 崔贞 黄艳平 朱全刚
摘 要 本文以2020年版《药物临床试验质量管理规范》《药物临床试验数据现场核查要点》《药物临床试验机构管理规定》为基础,以试验合规性、数据真实性、操作规范性、记录完整性为核心,归納皮肤病药物临床试验中知情同意、入排审核、研究病历书写、实验室检查、药物疗效评估、药物和生物样本管理等环节的质量控制要点,着重分析皮肤病药物临床试验的质量控制特点,以期为皮肤病药物临床试验质量控制提供参考,从而为安全、有效的皮肤病药物上市保驾护航。
关键词 皮肤病 药物临床试验 质量控制
中图分类号:R-3; R951 文献标志码:C 文章编号:1006-1533(2023)11-0059-04
引用本文 时歆未, 崔贞, 黄艳平, 等. 皮肤病药物临床试验的质量控制要点及特征分析[J]. 上海医药, 2023, 44(11): 59-62; 70.
基金项目:上海市科学技术委员会课题(20DZ2255200;21S21900900;23S21900800)
Key points and characteristics of quality control in clinical trials of dermatological drugs
SHI Xinwei, CUI Zhen, HUANG Yanping, ZHU Quangang
(PhaseⅠClinical Trial Center of Shanghai Skin Disease Hospital, Shanghai 200443, China)
ABSTRACT Based on the 2020 edition of “Good Clinical Practice”, “Key Points of On-site Drug Clinical Trial Date Inspection”, and “Regulations on the Management of Drug Clinical Trial Institutions”, with test compliance, data authenticity, operation standardization, and record integrity as the core, the key points of quality control in clinical trials of dermatological drugs such as informed consent, inclusion review, research medical record writing, laboratory examination, drug efficacy evaluation, drug and biological sample management were summarized and the quality control characteristics of clinical trials of dermatological drugs were focused on, so as to provide reference for the quality control of clinical trials of dermatological drugs and escort for their safe and effective marketing.
KEY WORDS skin disease; drug clinical trials; quality control
药物是皮肤病治疗最主要的手段,临床试验作为皮肤病治疗药物研发的关键环节及药品审评、审批的重要依据,也是皮肤病药物上市的必经之路。2020年中国药物临床试验登记与信息公示平台登记的皮肤类药物注册临床试验占同期全部药物临床试验的6.16%[1],2021年皮肤类药物临床试验项目登记量达到186项,较2020年增长18.4%。近年来,诺华、赛诺菲、礼来、杨森、辉瑞等知名跨国医药企业纷纷涉足皮肤病新药研发领域,多个重磅产品获准上市,皮肤科创新药的临床试验项目日趋增多。为进一步提高皮肤科新药临床试验质量,亟需加强皮肤病药物临床试验的质量控制,通过质量控制的事先预防和事后整改,确保试验合规、数据真实、操作规范、记录完整,也有利于提升药物临床试验机构的竞争力。……
